Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U. Food and Drug Administration's vaccine ...
Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. | Eli Lilly is making investments ...
This healthcare giant is trading at a discounted price today.
Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...
March 13 (Reuters) - A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of ...
Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...
Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising breast cancer drug ...
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for ...
US medicines giant sees additional 1,087 spaces as ‘absolute necessity’ but plan is running into local opposition ...
Roche's shares declined sharply after its breast cancer drug, giredestrant, failed a key trial. The drug didn't show meaningful progress when combined with Ibrance. Despite this, analysts see ...
A dish of living human neurons has been taught to play Doom. No, it isn’t conscious or watching the screen the way players do. But it is learning to respond to signals in a way that produces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results